Genitourinary tumors consist of a large variety of malignancies located in the urinary and the reproductive systems, mainly including prostate cancer, bladder cancer, and renal tumors. Apart from surgeries, various systemic treatments have been used for the whole-course management of genitourinary tumors, including radiation therapy, chemotherapy, and hormonal therapy. However, the characteristics of progression, metastasis, and drug resistance deriving from tumors require and breed novel treatments. Furthermore, exploring biomarkers of genitourinary tumors at the early stage is also beneficial to strengthen the management of patients with tumors. Additionally, the diagnostic and prognostic value of the potential biomarkers for immunotherapy and combined therapy of genitourinary tumors are underexplored.
On the basis of precision treatments, the advent of immune-based therapies, including immune checkpoint inhibitors (ICIs, antibodies targeting PD-L1 /PD-1 and CTLA-4 pathways), tumor vaccines, and other therapies, has extended the scope of treatment modalities. FDA has until now approved the clinical application of immune checkpoint inhibitors in a wide range of diseases including some types of genitourinary tumors, whereas not all patients with genitourinary tumors are suitable for immune-based therapies, therefore, the understanding of its underlying mechanism is key to develop effective treatments based on current ICI-based immunotherapy.
In this Research Topic, we aim to explore the potential biomarkers and drug targets for immunotherapy of genitourinary tumors. With the utilization of those biomarkers and drug targets, potential patients who are sensitive to targeted therapy or immunotherapy can be selected, and the diagnostic, therapeutic, and prognostic effect of the biomarkers and drug targets can strengthen the whole-course management of patients with genitourinary tumors.
We welcome submissions of Original Research, Review articles, Perspectives, and Mini-Review, covering, but not limited to, the following bullet points:
1. Novel immunotherapeutic drugs or targeted therapeutic drugs for genitourinary tumors;
2. Potential biomarkers for predicting the diagnostic, therapeutic, and prognostic value in patients with genitourinary tumors;
3. New clinical studies focusing on immunotherapy in patients with genitourinary tumors;
4. Molecular mechanism involved in the progression of genitourinary tumors;
5. Novel approaches for biomarker detection using tissue, blood, or urine;
6. Findings of novel immune checkpoint molecules in genitourinary tumors;
7. Development of ICI-based combinational therapy for genitourinary tumors.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Genitourinary tumors consist of a large variety of malignancies located in the urinary and the reproductive systems, mainly including prostate cancer, bladder cancer, and renal tumors. Apart from surgeries, various systemic treatments have been used for the whole-course management of genitourinary tumors, including radiation therapy, chemotherapy, and hormonal therapy. However, the characteristics of progression, metastasis, and drug resistance deriving from tumors require and breed novel treatments. Furthermore, exploring biomarkers of genitourinary tumors at the early stage is also beneficial to strengthen the management of patients with tumors. Additionally, the diagnostic and prognostic value of the potential biomarkers for immunotherapy and combined therapy of genitourinary tumors are underexplored.
On the basis of precision treatments, the advent of immune-based therapies, including immune checkpoint inhibitors (ICIs, antibodies targeting PD-L1 /PD-1 and CTLA-4 pathways), tumor vaccines, and other therapies, has extended the scope of treatment modalities. FDA has until now approved the clinical application of immune checkpoint inhibitors in a wide range of diseases including some types of genitourinary tumors, whereas not all patients with genitourinary tumors are suitable for immune-based therapies, therefore, the understanding of its underlying mechanism is key to develop effective treatments based on current ICI-based immunotherapy.
In this Research Topic, we aim to explore the potential biomarkers and drug targets for immunotherapy of genitourinary tumors. With the utilization of those biomarkers and drug targets, potential patients who are sensitive to targeted therapy or immunotherapy can be selected, and the diagnostic, therapeutic, and prognostic effect of the biomarkers and drug targets can strengthen the whole-course management of patients with genitourinary tumors.
We welcome submissions of Original Research, Review articles, Perspectives, and Mini-Review, covering, but not limited to, the following bullet points:
1. Novel immunotherapeutic drugs or targeted therapeutic drugs for genitourinary tumors;
2. Potential biomarkers for predicting the diagnostic, therapeutic, and prognostic value in patients with genitourinary tumors;
3. New clinical studies focusing on immunotherapy in patients with genitourinary tumors;
4. Molecular mechanism involved in the progression of genitourinary tumors;
5. Novel approaches for biomarker detection using tissue, blood, or urine;
6. Findings of novel immune checkpoint molecules in genitourinary tumors;
7. Development of ICI-based combinational therapy for genitourinary tumors.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
